Rezolute, Inc. (NASDAQ:RZLT) Stock Has Average Price Target of $11.22 According to Analysts

Rezolute logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts hold a “Moderate Buy” consensus on Rezolute, with 12 buy ratings and two sell ratings among 14 brokerages. The average 12-month price target is $11.22.
  • Rezolute shares opened at $3.95, with a 52-week range of $1.07 to $11.46 and a market capitalization of approximately $382 million. The company recently reported a quarterly loss of $0.20 per share, missing estimates by $0.05.
  • Institutional investors own approximately 82.97% of Rezolute’s stock. The clinical-stage biopharmaceutical company is developing RZ358, an investigational therapy for congenital hyperinsulinism and other disorders involving excessive insulin activity.
  • MarketBeat previews top five stocks to own in December.

Shares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fourteen brokerages that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and twelve have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $11.22.

A number of equities research analysts have weighed in on the stock. Citigroup restated a "market outperform" rating on shares of Rezolute in a report on Thursday, October 15th. Craig Hallum raised Rezolute from a "hold" rating to a "buy" rating and increased their target price for the company from $4.00 to $7.00 in a report on Tuesday, September 29th. Lake Street Capital boosted their target price on Rezolute from $9.00 to $12.00 and gave the company a "buy" rating in a research report on Tuesday, October 6th. Cantor Fitzgerald raised shares of Rezolute from a "neutral" rating to an "overweight" rating in a report on Monday, October 5th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Rezolute in a research report on Thursday, October 15th.

Read Our Latest Research Report on Rezolute

Rezolute Stock Performance

NASDAQ:RZLT opened at $3.95 on Monday. The stock has a market capitalization of $382.08 million, a P/E ratio of -5.20 and a beta of 0.65. Rezolute has a 1 year low of $1.07 and a 1 year high of $11.46. The firm has a 50 day moving average of $4.25 and a 200-day moving average of $3.88.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Thursday, September 24th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). As a group, analysts forecast that Rezolute will post -0.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Sequoia Financial Advisors LLC bought a new position in Rezolute during the 2nd quarter valued at about $75,000. WINTON GROUP Ltd acquired a new position in shares of Rezolute in the second quarter valued at about $88,000. Integrated Wealth Concepts LLC bought a new stake in shares of Rezolute during the 2nd quarter worth $143,000. Wellington Management Group LLP acquired a new position in shares of Rezolute during the second quarter worth $276,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Rezolute during the 2nd quarter valued at $267,000. Institutional investors own 82.97% of the company's stock.

About Rezolute

(Get Free Report)

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company's lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor.

RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.

Featured Articles

Analyst Recommendations for Rezolute (NASDAQ:RZLT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Rezolute Right Now?

Before you consider Rezolute, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.

While Rezolute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines